Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each country, as well as annualized case counts projected to the national population. Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years and the patient populations in the other countries under study over 10 years. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities are also forecast across the major pharmaceutical markets.

Clarivate Epidemiology’s AF forecast answers the following questions:

  • How will change in the levels of exposure to known risk or protective factors affect the number of people living with AF?
  • Of all people with AF, how many in each country have been formally diagnosed?
  • Of all people diagnosed with AF, how many in the mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AF over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology provides at least twenty years of forecast data for the following AF patient populations:

  • Total AF prevalent cases.
  • Diagnosed AF prevalent cases.
  • Undiagnosed AF prevalent cases.
  • Diagnosed AF prevalent cases by subtype scheme.
  • Diagnosed AF prevalent cases by hypertension status.
  • Diagnosed AF prevalent cases by valvular heart disease status.
  • Diagnosed AF prevalent cases by heart failure status.
  • Diagnosed AF prevalent cases by CHADS2 score scheme.
  • Diagnosed AF drug-treated prevalent cases.
  • Diagnosed AF non-drug-treated prevalent cases.

… and many more (details available on request).

Note: Coverage may vary by country and region.

Table of contents


Related Market Assessment Reports

Report
Atrial Fibrillation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Atrial Fibrillation (US)
Atrial fibrillation (AF) is a common arrhythmia characterized by irregular, often rapid heartbeats in the atria, increasing the risk of stroke and cardiovascular complications. Management typically…
Report
Heart Failure – Geographic Focus: China – China In-Depth – Heart Failure
Heart failure remains a significant public health challenge in China, driven by urbanization, an aging population, and sedentary lifestyles. The treatment of acute heart failure (AHF) still largely…
Report
Ocular Pain – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of ocular pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…